Charles River Laboratories International Inc. (NYSE:CRL) shares gapped up prior to trading on Thursday . The stock had previously closed at $83.32, but opened at $83.46. Charles River Laboratories International shares last traded at $84.17, with a volume of 100,593 shares traded.

Several brokerages have commented on CRL. Credit Suisse Group AG began coverage on shares of Charles River Laboratories International in a report on Monday, June 20th. They issued a “neutral” rating and a $84.00 target price for the company. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $92.00 target price for the company in a report on Friday, June 17th. KeyCorp reiterated a “hold” rating and issued a $77.00 target price on shares of Charles River Laboratories International in a report on Sunday, May 22nd. Barclays PLC raised their target price on shares of Charles River Laboratories International from $60.00 to $65.00 and gave the stock an “underweight” rating in a report on Friday, May 20th. Finally, Gabelli began coverage on shares of Charles River Laboratories International in a report on Tuesday, April 26th. They issued a “buy” rating and a $96.00 target price for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $82.00.

The company has a market cap of $3.99 billion and a P/E ratio of 26.00. The company’s 50-day moving average is $83.88 and its 200 day moving average is $78.54.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, May 4th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.90 by $0.08. During the same quarter in the previous year, the firm posted $0.79 earnings per share. The company had revenue of $354.90 million for the quarter, compared to analyst estimates of $354.92 million. Charles River Laboratories International’s quarterly revenue was up 10.8% compared to the same quarter last year. Analysts forecast that Charles River Laboratories International Inc. will post $4.39 EPS for the current year.

In other news, Director George Massaro sold 985 shares of the business’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $82.17, for a total transaction of $80,937.45. Following the completion of the transaction, the director now directly owns 13,020 shares in the company, valued at approximately $1,069,853.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO John J. Crowley sold 1,913 shares of the business’s stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $85.00, for a total value of $162,605.00. Following the transaction, the chief accounting officer now owns 6,883 shares of the company’s stock, valued at $585,055. The disclosure for this sale can be found here.

Several institutional investors recently bought and sold shares of CRL. Mutual of America Capital Management LLC raised its position in Charles River Laboratories International by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 31,278 shares of the company’s stock valued at $2,514,000 after buying an additional 164 shares during the last quarter. Great West Life Assurance Co. Can raised its position in shares of Charles River Laboratories International by 1.4% in the fourth quarter. Great West Life Assurance Co. Can now owns 27,994 shares of the company’s stock valued at $2,255,000 after buying an additional 400 shares in the last quarter. Rhumbline Advisers raised its position in shares of Charles River Laboratories International by 0.6% in the fourth quarter. Rhumbline Advisers now owns 86,645 shares of the company’s stock valued at $6,965,000 after buying an additional 477 shares in the last quarter. Retirement Systems of Alabama raised its position in shares of Charles River Laboratories International by 1.0% in the fourth quarter. Retirement Systems of Alabama now owns 59,909 shares of the company’s stock valued at $4,816,000 after buying an additional 585 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of Charles River Laboratories International by 2.1% in the fourth quarter. GSA Capital Partners LLP now owns 59,361 shares of the company’s stock valued at $4,772,000 after buying an additional 1,209 shares in the last quarter.

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.